Press release
27 March 2017
Respiratory disease cost jumps to $6 billion per year
Respiratory disease continues to make a substantial contribution to New Zealand’s health burden. Over the past 15 years,
hospitalisation rates have increased for bronchiectasis, childhood bronchiolitis and total respiratory disease.
The Impact of Respiratory Disease in New Zealand: 2016 Update, commissioned by the Asthma and Respiratory Foundation NZ, reported that respiratory disease accounted for one in 10
overnight hospitalisations and costs the country more than $6 billion per year.
Six indicators were assessed for the report, including asthma, bronchiectasis, childhood bronchiolitis and pneumonia,
chronic obstructive pulmonary disease (COPD) and total respiratory disease.
A high degree of socio-economic and ethnic inequality was highlighted as “by far the most relentless and disturbing
pattern” the report said.
Pacific peoples’ respiratory health was consistently poorest across all indicators, followed by Māori. Across all age
groups, respiratory hospitalisation rates are much higher for Pacific peoples (3.1 times higher) and Māori (2.4 times
higher) than for other ethnic groups.
High inequalities in respiratory hospitalisations by socio-economic deprivation were prevalent. Differences between the
most and least deprived areas range from a rate ratio of 2.9 for childhood pneumonia, 5.2 for childhood bronchiolitis
and 5.7 for adult COPD.
The report highlighted the effect of deprivation as “near exponential”.
While overall mortality rates caused by respiratory disease have declined slightly in the last 15 years, mortality rates
are two times higher for both Māori and those living in the most deprived areas.
In November 2015, the Foundation launched the New Zealand Respiratory Strategy, a call to action for urgent
recommendations to reduce the incidence and impact of respiratory disease, and eliminate equalities in respiratory
health.
ENDS
• The Impact of Respiratory Disease in New Zealand: 2016 Update reports the cost of respiratory disease as $5.5 billion per year